Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 89.42% | -83.75% | -6.66% | -344.84% | -685.00% |
| Total Depreciation and Amortization | 100.00% | -33.33% | -40.00% | -86.67% | -95.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.22% | 118.15% | -100.67% | 93.74% | 121.82% |
| Change in Net Operating Assets | -253.64% | -45.59% | 256.06% | 83.87% | -51.51% |
| Cash from Operations | 74.33% | -21.29% | -0.83% | -14.65% | -492.87% |
| Capital Expenditure | -- | 114.29% | 28.57% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 114.29% | 28.57% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -110.00% | -11.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.62% | -21.11% | -0.75% | -125.73% | -484.49% |